As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specia 24 May 2019
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to w 17 May 2019
Learning from the standards set by the USA.Europe and Brazil.Colombia is fast catching up in making the country an attractive place to research.seek approval fo 13 May 2019
Canada-based Canopy Growth is the world’s largest cannabis company, by market cap, and it aspires to be a world leader in developing the drug as a medicine. 17 April 2019
The end of a drug’s exclusivity period can result in expensive patent litigation, and IP lawyer Kent Walker has identified an emerging trend that could present 18 March 2019
Aspirin may be over 100 years old, but OtiTopic believes the potential of the analgesic workhorse to provide innovative therapies is yet to be exhausted. 1 March 2019
Big pharma companies’ quarterly and annual results are rarely as relevant as those of retailers, airlines and many other big firms because of the tendency of th 13 February 2019
When Gilead Sciences presents its annual results on Monday, there will be a few eyes on the latest sales of Biktarvy (bictegravir/emtricitabine/tenofovir alafen 4 February 2019
Members of the deals team at Arix Bioscience, a London-listed venture capital (VC) firm specializing in biotech, are so well-connected that they will never lack 4 January 2019
The runaway success of Adcetris (brentuximab vedotin) has ensured the future of Seattle Genetics as antibody-drug conjugate specialist, but chief executive Clay 13 December 2018
In the USA alone, more than 10% of adults or adolescents take antidepressants, and fully two-thirds of these people do not respond to first-line treatment, norm 26 November 2018
Novo Nordisk’s (NOV: N) decision to spend up to $800 million buying the synthetic glucose specialist Ziylo has thrown a spotlight on Unit DX, a biotech incubato 15 November 2018
As far as PARP inhibitors are concerned, AstraZeneca stole the show at the annual congress of ESMO this month, with the SOLO-1 trial of Lynparza (olaparib) show 9 November 2018
At the annual congress of the European Society of Medical Oncology (ESMO) this week, AstraZeneca’s Susan Galbraith told The Pharma Letter the firm was “very pro 25 October 2018
While PARP blocker rivals AstraZeneca and Tesaro chase the prize of a first-line ovarian cancer indication, Clovis Oncology is highlighting what it sees as prom 19 October 2018
Dr Martin Huber, chief medical officer of Tesaro, spoke with The Pharma Letter about his firm’s runner in the PARP blocker field, Zejula (niraparib). 9 October 2018
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.